Bioavailability: Difference between revisions
From WikiLectures
(minor) |
(minor) |
||
Line 11: | Line 11: | ||
'''Absolute bioavailability''' | '''Absolute bioavailability''' | ||
[[File:AUC_IVPO.svg| right | 250px |]] | [[File:AUC_IVPO.svg| right|250px|The plasma concentration (C) over time (t) graph]] | ||
:It is the comparison of the per os F to the intravenous F | :It is the comparison of the per os F to the intravenous F | ||
::<math> {F_{abs}} = {AUC_{P.O.} \times D_{I.V.}\over AUC_{I.V.}\times D_{P.O.}} </math> | ::<math> {F_{abs}} = {AUC_{P.O.} \times D_{I.V.}\over AUC_{I.V.}\times D_{P.O.}} </math> |
Revision as of 01:28, 5 July 2014
Definition
- Bioavailability (F) is a pharmacokinetic parameter representing the fraction of a drug dose that reaches the systemic circulation unaltered.
Characteristics
- The greater the F, the greater the amount of drug that reaches the systemic circulation, and thus the greater the drug concentration in plasma and vice versa
- The route with the highest F (F=1) is via intravenous (I.V.) administration.
- The second highest F is achieved through inhalation.
- The parenteral routes of drug administration have low F because all the drug absorbed by the GIT, passes through the hepatic circulation undergoing *first pass metabolism, prior entering to the systemic circulation.
Types
Absolute bioavailability
- It is the comparison of the per os F to the intravenous F
- where
- AUCP.O.: area under the curve for the oral route
- AUCI.V.: area under the curve for the intravenous route
- DP.O.: dose administered from oral route
- DI.V.: dose administers from intravenous route
Relative bioavailability
- It is the comparison of the per os F to another administration route, other than intravenous.